Press

2021-05-24

Kancera announces that an application for a clinical phase IIa study with KAND567 after heart attack has been submitted to the UK Medicines Agency (MHRA)

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the...

Read More
2021-05-21

Interim report for first quarter 2021, 1 January – 31 March 2021

First quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...

Read More
2021-04-21

Kancera provides an update on the development of the company’s pharmaceutical project and nominates a new drug candidate

two thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter, successful scaling up of production of the drug candidate...

Read More
2021-03-22

Pioneering research results for Kancera’s Fractalkine blockers may pave the way for new treatment for ovarian cancer

Kancera AB (Nasdaq First North Premier Growth Market: KAN) reports preclinical research results, which show that the company's Fractalkine blockers have the potential to disrupt cancer cells' resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer...

Read More
2021-02-19

Interim report for fourth quarter 2020, 1 January – 31 December 2020

Fourth quarter in brief as well as the period 1 January – 31 December 2020 Net sales for the period (January to December) amounted to SEK 0,1 million (3,2 million), of which the fourth quarter contributed SEK 0 million...

Read More
2021-01-15
2021-01-15

Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology

This is a translation of a press release in Swedish published December 21, 2020

Read More
2020-12-02

Agreement on development of HDAC6 inhibitors discontinued.

Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for the development of Kancera's series of HDAC6 inhibitors and...

Read More
2020-11-20

Interim report for the third quarter 2020, January 1st – September 30th, 2020

Third quarter in brief as well as the period 1 January – 30 September 2020 Net sales for the period (January to September) amounted to SEK 0,09 million (3,3 million), of which the third quarter contributed SEK 0,05 million...

Read More
2020-10-01

Kancera starts study in covid-19 patients

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried out in collaboration with Capio St. Göran's Hospital and...

Read More